Visual abstract | Key updates to the GRAPPA treatment recommendations for PsA

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing key updates to the GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) recommendations for the treatment of psoriatic arthritis.

The original GRAPPA guidelines were published in 2009 and revised in 2015.¹ These new, updated, 2021 guidelines aim to offer recommendations for the use of therapies for the six psoriatic arthritis domains (peripheral arthritis, axial disease, enthesitis, dactylitis, psoriasis, and nail disease), giving guidance on treatments that can and cannot be used with associated conditions (inflammatory bowel disease and uveitis) and other comorbidities. Subcommittees were formed from GRAPPA members, with systemic literature searches completed using data published between 2013 and 2020. Treatment pathway recommendations consider the domains involved in psoriatic arthritis, patient treatment preferences, and current therapies. Additional position statements were added to address treatment with biosimilars and tapering, plus a revised research agenda.¹